Pulmatrix

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative inhaled therapies for serious pulmonary and non-pulmonary diseases. Utilizing its patented iSPERSE technology, Pulmatrix aims to enhance patient care by delivering therapeutics directly to the lungs. The company operates in the healthcare sector, primarily targeting patients with severe respiratory conditions. Pulmatrix's business model involves the research, development, and commercialization of its proprietary drug formulations. Revenue is generated through partnerships, licensing agreements, and eventual product sales. The company collaborates with partners like Sensory Cloud to market and distribute products such as FEND, an over-the-counter nasal hygiene product designed to suppress exhaled airborne particles. Pulmatrix's pipeline includes various therapeutic candidates aimed at addressing unmet medical needs in respiratory health.

Keywords: biopharmaceutical, inhaled therapies, pulmonary diseases, iSPERSE technology, respiratory health, clinical-stage, drug development, partnerships, licensing, FEND.